KX 01

Drug Profile

KX 01

Alternative Names: KX-01; KX-2391

Latest Information Update: 31 Mar 2017

Price : $50

At a glance

  • Originator Kinex Pharmaceuticals
  • Developer Athenex; Hanmi Pharmaceutical; Kinex Pharmaceuticals; PharmaEssentia Corporation
  • Class Acetamides; Antineoplastics; Morpholines; Pyridines; Skin disorder therapies; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Caspase stimulants; Interleukin 2 inhibitors; Keratinocyte inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Src-Family kinase inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Psoriasis
  • Phase I/II Solid tumours
  • Phase I Actinic keratosis; Acute myeloid leukaemia
  • No development reported Prostate cancer

Most Recent Events

  • 27 Jan 2017 Athenex reacquires the right to market and commercialise KX 01 for Actinic keratosis in China
  • 27 Jan 2017 PharmaEssentia maintains the rights to develop and commercialise KX 01 for Actinic keratosis in Taiwan and for Psoriasis in Taiwan and China
  • 15 Dec 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top